• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Curr Pharm Des . Repurposing Drugs for the Management of Patients With Confirmed Coronavirus Disease 2019 (COVID-19)

tetano

Editor, Senior Moderator
Curr Pharm Des


. 2020 Jul 7.
doi: 10.2174/1381612826666200707121636. Online ahead of print.
Repurposing Drugs for the Management of Patients With Confirmed Coronavirus Disease 2019 (COVID-19)


Evellyn Claudia Wietzikoski Lovato[SUP] 1 [/SUP], Lorena Neris Barboza[SUP] 1 [/SUP], Samantha Wietzikoski[SUP] 1 [/SUP], Amanda Nascimento Vasques de Souza[SUP] 1 [/SUP], Pablo Alvarez Auth[SUP] 2 [/SUP], Arquimedes Gasparotto Junior[SUP] 3 [/SUP], Francislaine Aparecida Dos Reis L?vero[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), termed coronavirus disease 2019 (COVID-19) by the World Health Organization, is a newly emerging zoonotic agent that emerged in China in December 2019. No specific treatment for COVID-19 is currently available. Usual palliative treatment includes maintaining hydration and nutrition and controlling fever and cough. The clinical severity and extent of transmission need to be determined, and therapeutic options need to be developed and optimized.
Methods: The present review discusses the recent repurposing of drugs for COVID-19 treatment.
Results: Several compounds, including remdesivir, lopinavir, ritonavir, interferon-β, ribavirin, chloroquine/hydroxychloroquine, azithromycin, tocilizumab, and ivermectin, have emerged as promising alternatives. They block the virus from entering host cells, prevent viral replication, and attenuate exacerbation of the host's immune response.
Conclusion: Although some evidence indicates the positive actions of different classes of compounds for the treatment of COVID-19, few clinical assays have been established to definitively demonstrate their therapeutic value in humans. Multicenter clinical studies are urgently needed to validate and standardize therapeutic regimens that involve these agents. Although science has not yet presented us with a specific drug against COVID-19, the repurposing of drugs appears to be promising in our fight against this devastating disease.

Keywords: azithromycin; chloroquine; ivermectin; lopinavir; remdesivir; ribavirin..
 
Back
Top Bottom